OncoRock Therapeutics

Biotechnology · Cell & Gene Therapy

Overview

OncoRock Therapeutics develops next-generation cancer immunotherapy through precision oncology, advancing innovative therapies for difficult-to-treat tumors.

Funding and backers

Total raised
$125k
1 round on record
Latest round
$125k
Convertible Note · Oct 2025 · 12 mo ago
The money's age
Due for its next round
12 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 14, 2025 Raised a round Convertible Note $125k · SEC Form D 2025 Founded
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note Oct 2025 $125k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity OncoRock Therapeutics Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Alan TackettExecutive Officer, DirectorSEC Form D
Brian KossExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Adventris Pharmaceuticals, Kopra Bio
General Catalyst
backs Waypoint Bio
F-Prime Capital
backs AvenCell
Bayern Kapital
backs T-Curx
Meta Planet
backs Kopra Bio
Multimodal Ventures
backs Kopra Bio
Similar startupsby what they do, their industry and backers
Haptena TherapeuticsFounded 2025
Haptena Therapeutics develops next-generation immunotherapies for oncogene-driven cancers, integrating precision oncology and immune…
Adventris Pharmaceuticals
Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy.
Signadori BioFounded 2024
Signadori Bio is a preclinical stage biopharmaceutical company developing a next generation in vivo monocyte immunotherapy to treat solid…
T-CurxVenture round · 6 mo ago · Founded 2017
T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges…
Kopra Bio
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
CellVax TherapeuticsVenture round $2.1M · 2 yr ago · Founded 2020 · 1-10 employees
At CellVax Therapeutics, we are developing the Next Generation of Personalized Immunotherapy.

Financials

Total raised
$125k
Latest round
Convertible Note
Funding rounds
1
Funding rounds
Round Announced Amount
Convertible Note 2025 $125k Details

People

Alan Tackett
Executive Officer, Director
SEC Form D
Brian Koss
Executive Officer, Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Little Rock United States
HQ
OncoRock Therapeutics
401 S. Cedar Street, Little Rock, AR 72205
company site